Live cell images of hMSCs number after 21 days <i>in vitro</i>.

<p>Shown are hMSCs of osteoporotic (left) and non osteoporotic (right) donors in presence of etched (1^st row) or ground Ti-40Nb (2^nd row), Ti-6Al-4V (3^rd row) or without Ti (4^th row) in presence of BDNF (A), ACh (B), Nic (C) or without pharmaceuticals serving as controls (D). White arrows indicate RS cells. The images show cells of different donors as typical representative of 4 independent experiments. Black regions at the margin of pictures show Ti alloys. Scale bar shown in A applies to all photographs in this figure.</p

Live cell images of hMSCs after 14 days of differentiation in osteogenic medium <i>in vitro</i>.

<p>Shown are hMSCs of osteoporotic (left) and non osteoporotic (right) donors in presence of etched (1^st row) or ground Ti-40Nb (2^nd row), Ti-6Al-4V (3^rd row) or without Ti (4^th row) in presence of BDNF (A), ACh (B), Nic (C) or without pharmaceuticals serving as controls (D). White arrows indicate mineral. The images show cells of different donors as typical representative of 4 independent experiments. Black regions at the margin of pictures show Ti alloys. Scale bar shown in A applies to all photographs in this figure.</p

Relative cell number of hMSCs of osteoporotic (grey boxplots) and non osteoporotic (white boxplots) donors in presence of etched or ground Ti-40Nb, Ti-6Al-4V as well as without Ti with or without pharmaceuticals.

<p>Shown is the effect of Ti alloys on cell number after 14 d (A) and 21 d (B) of <i>in vitro</i> incubation. The grey line represents cells at time point 0 d without Ti and without pharmaceuticals. A value of p ≤ 0.05 was considered to be significant and is indicated with one asterisk.</p

Live cell images of hMSCs number after 14 days <i>in vitro</i>.

<p>Shown are hMSCs of osteoporotic (left) and non osteoporotic (right) donors in presence of etched (1^st row) or ground Ti-40Nb (2^nd row), Ti-6Al-4V (3^rd row) or without Ti (4^th row) in presence of BDNF (A), ACh (B), Nic (C) or without pharmaceuticals serving as controls (D). The images show cells of different donors as typical representative of 4 independent experiments. Black regions at the margin of pictures show Ti alloys. Scale bar shown in A applies to all photographs in this figure.</p

Live cell images of hMSCs after 21 days of differentiation in osteogenic medium <i>in vitro</i>.

<p>Shown are hMSCs of osteoporotic (left) and non osteoporotic (right) donors in presence of etched (1^st row) or ground Ti-40Nb (2^nd row), Ti-6Al-4V (3^rd row) or without Ti (4^th row) in presence of BDNF (A), ACh (B), Nic (C) or without pharmaceuticals serving as controls (D). White arrows indicate mineral. The images show cells of different donors as typical representative of 4 independent experiments. Black regions at the margin of pictures show Ti alloys. Scale bar shown in A applies to all photographs in this figure.</p

Live cell images of hMSCs number after 7 days <i>in vitro</i>.

<p>Shown are hMSCs of osteoporotic (left) and non osteoporotic (right) donors in presence of etched (1^st row) or ground Ti-40Nb (2^nd row), Ti-6Al-4V (3^rd row) or without Ti (4^th row) in presence of BDNF (A), ACh (B), Nic (C) or without pharmaceuticals serving as controls (D). The images show cells of different donors as typical representative of 4 independent experiments. Black regions at the margin of pictures show Ti alloys. Scale bar shown in A applies to all photographs in this figure.</p

Live cell images of hMSCs after 7 days of differentiation in osteogenic medium <i>in vitro</i>.

<p>Shown are hMSCs of osteoporotic (left) and non osteoporotic (right) donors in presence of etched (1^st row) or ground Ti-40Nb (2^nd row), Ti-6Al-4V (3^rd row) or without Ti (4^th row) in presence of BDNF (A), ACh (B), Nic (C) or without pharmaceuticals serving as controls (D). The images show cells of different donors as typical representative of 4 independent experiments. Black regions at the margin of pictures show Ti alloys. Scale bar shown in A applies to all photographs in this figure.</p

Baseline patient characteristics.

<p>P-values reveals differences between colonized and non-colonized patients. Allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; ELN, European Leukemia Net; CR, complete remission; MAC, myeloablative conditioning; PBSC, peripheral blood stem cells; MRD, matched related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; CMV, cytomegalovirus; GvHD, Graft versus Host Disease, HCT-CI, hemtaopoetic stem cell transplantation comorbidity index.</p

<i>Stenotrophomonas maltophilia</i> colonization during allogeneic hematopoietic stem cell transplantation is associated with impaired survival - Fig 2

<p><b>Cumulative incidence of non-relapse related mortality (A) and cumulative incidence of relapse (B)</b> after allogeneic hematopoietic stem cell transplantation, stratified by colonized (dotted line) and non-colonized (solid line) patients.</p

Transplant-related characteristics and outcomes.

<p>P-values reveal differences between colonized and non-colonized patients. ANC, absolute neutrophil count; PLT, platelets; aGvHD, acute Graft versus Host Disease; cGvHD, chronic Graft versus Host Disease MDRO, multidrug resistant organisms; BIS, bloodstream infection; allo-HSCT, allogeneic hematopoietic stem cell transplantation. OS, Overall survival, 95% CI, 95% confidence interval; NRM, non-relapse mortality; GvHD, Graft versus Host Disease.</p